| TCH方案在Her-2阳性乳腺癌新辅助治疗的临床疗效观察 |
| 投稿时间：2011-05-12 修订日期：2011-06-02 点此下载全文 |
| 引用本文：王敏,何劲松,陈伟财,王先明.TCH方案在Her-2阳性乳腺癌新辅助治疗的临床疗效观察[J].医学研究杂志,2012,41(2):85-87 |
| DOI：
|
| 摘要点击次数: 1243 |
| 全文下载次数: 1031 |
|
| 基金项目:深圳市科技和信息局重点项目（2008011004） |
|
| 中文摘要:目的探讨TCH（多西他赛+卡铂+曲妥珠单抗）方案在Her-2阳性乳腺癌新辅助治疗中的临床疗效。方法对21例Her-2阳性乳腺癌（ⅡB期~ⅢC期）术前行TCH方案的新辅助治疗4~6个周期，评价临床疗效，并中位随访2年观察无病生存率及总生存率。结果21例患者中CR 16例（76.19%），其中达到PCR 13例（61.90%），PR 3例（14.29%），SD 2例（952%）。总有效率 (CR+PR)达：90.48%，2年的无病生存率为95.23%，总生存率为100%。结论应用TCH方案行新辅助治疗可有效提高Her-2阳性乳腺癌患者的临床缓解率，使一部分患者获得保乳手术的机会，提高手术成功率，并改善患者的生存率。 |
| 中文关键词:乳腺癌 新辅助治疗 曲妥珠单抗 Her-2阳性 |
| |
| Clinical Efficacy Observations of Neoadjuvant Therapy with TCH Regimen in Treatment of Her-2-overexpressing Breast Cancer |
|
|
| Abstract:ObjectiveTo observe the clinical efficacy of neoadjuvant therapy with TCH regimen(Trastuzumb combined with docetaxel and carbopatin) in treatment of Her-2-overexpressing breast cancer. MethodsTwenty one patients with Her-2（+++）breast cancer（clinical stage ⅡB-ⅢC）received neoadjuvant therapy with TCH regimen 4-6 cycles before operation. Clinical effect and disease-free survival rate（DFS）and overall survival rate（OS） were observed and compared during mean 2 years follow-up. ResultsAmong 21 patients after neoadjuvant therapy，16 cases were complete remission（CR）（76.19%），13 case had pathological complete response（PCR）（61.90%），3 cases were partial remission（PR）（14.29%），and 2 cases were steady（SD）（9.52%）.Total clinical response rate（CR+PR） was 90.48%.DFS of two years was 95.23%,and OS of two years was 100%.ConclusionNeoadjuvant therapy using TCH regimen can improve clinical remission rate and survival rate in Her-2-overexpressing breast cancer，and can obtain chance of breast-conserving surgery therapy and increase achievement ratio of surgery. |
| keywords:Breast cancer Neoadjuvant therapy Trastuzumb Her-2-overexpressing |
| 查看全文 查看/发表评论 下载PDF阅读器 |
